Suggestions
Idioma
Guide for authors
Searcher
Journal Information
Cite
Cite
Share
Download PDF
More article options
Visits
987
Review

Finerenone in heart failure with ejection fraction ≥40%: state of the art and future perspectives

Finerenona en la insuficiencia cardíaca con fracción de eyección ≥40%: estado del arte y perspectivas futuras
Visits
987
Pau Llàcera,b,
Corresponding author
paullacer@hotmail.com

Corresponding authors.
, Marta Cobo Marcosc,d, Julio Nuñezd,e, Luis M. Perez Belmontef,g,h, José Pérez Silvestrei, Marta Sanchez Martelesj,k, José Comin Coletl,m,ñ,
Corresponding author
josepcomin@gmail.com

Corresponding authors.
a Servicio de Medicine Interna, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
b Departamento de Medicina y Especialidades Médicas, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, Madrid, Spain
c Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Madrid, Spain
d Centro de Investigación Biomédica en Red (CIBER Cardiovascular), Madrid, Spain
e Servicio de Cardiología, Hospital Clínco Universitario Valencia, Valwencia, Spain; Universidad de Valencia, INCLIVA, Centro de Investigación Biomédica en Red (CIBER Cardiovascular), Madrid, Spain
f Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Málaga, Spain
g Instituto de Investigación Biomédica de Málaga (IBIMA) – Plataforma BIONAND, Málaga, Spain
h Universidad de Málaga, Málaga, Spain
i Servicio de Medicina Interna, Consorci Hospital General Universitari de Valencia, Valencia, Spain
j Hospital Clínico Universitario “Lozano Blesa”, Zaragoza, Spain
k Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain
l Area del Corazón, Hospital Universitario de Bellvitge, Universitat de Barcelona (UB), Barcelona, Spain
m Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain
ñ Centro de Investigación Biomédica en Red (CIBER Cardiovascular) CIBER-CV, Barcelona, Spain
Ver más
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract

Heart failure with ejection fraction ≥40% is associated with high mortality and risk of decompensation, as well as poorer quality of life. SGLT2 inhibitors are currently considered the standard therapy for these patients. However, despite treatment with these drugs, patients continue to have a high risk of adverse events. Overactivation of the mineralocorticoid receptor promotes the release of inflammatory and profibrotic factors, which contribute to the development and progression of this entity. However, not all mineralocorticoid receptor antagonists have demonstrated clinical benefit in these patients. The FINEARTS-HF study demonstrated that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, significantly reduces the risk of cardiovascular death or heart failure decompensation, with consistent results across all patient subgroups analyzed. Consequently, in the treatment of these patients the combination of SGLT2 inhibitors and finerenone should be considered.

Keywords:
Cardiovascular
Finerenone
Hospitalization
Heart failure
Heart failure with mildly reduced ejection fraction
Heart failure with preserved ejection fraction
Renal
Resumen

La insuficiencia cardiaca con fracción de eyección ≥40% se asocia con una elevada mortalidad y riesgo de descompensaciones, así como con peor calidad de vida. Actualmente los inhibidores SGLT2 constituyen el tratamiento de base en estos pacientes. Sin embargo, a pesar del tratamiento con estos fármacos, los pacientes continúan presentando un riesgo elevado de eventos adversos. La sobreactivación del receptor de mineralocorticoide promueve la liberación de factores inflamatorios y profibróticos, que contribuyen al desarrollo y progresión de esta entidad. Ahora bien, no todos los antagonistas del receptor de mineralocorticoide han demostrado beneficio clínico en estos pacientes. El estudio FINEARTS-HF demostró que finerenona, un antagonista del receptor de mineralocorticoide no esteroideo, reduce significativamente el riesgo de muerte cardiovascular o descompensaciones por insuficiencia cardiaca, con resultados consistentes en todos los subgrupos de pacientes analizados. En consecuencia, en el tratamiento de estos pacientes se debería considerar la combinación de inhibidores SGLT2 y finerenona.

Palabras clave:
Cardiovascular
Finerenona
Hospitalización
Insuficiencia cardiaca
Insuficiencia cardiaca con fracción de eyección levemente reducida
Insuficiencia cardiaca con fracción de eyección preservada
Renal

Article

These are the options to access the full texts of the publication Revista Clínica Española (English Edition)
Member
Si es usted socio de FESEMI siga los siguientes pasos:

Diríjase desde aquí a la web de la >>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.

Deslice el cursor hacia abajo hasta la sección "PUBLICACIONES" y pinche en "Revista Clínica Española":

>>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<<

Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
Revista Clínica Española (English Edition)
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
References
[1]
S.S. Martin, A.W. Aday, N.B. Allen, et al.
2025 Heart Disease and Stroke Statistics: a report of US and Global data from the American Heart Association.
Circulation, 151 (2025), pp. e41-e660
[2]
P.M. Seferović, P. Vardas, E.A. Jankowska, et al.
The heart failure association atlas: heart failure epidemiology and management statistics 2019.
Eur J Heart Fail, 23 (2021), pp. 906-914
[3]
M.S. Khan, I. Shahid, A. Bennis, A. Rakisheva, M. Metra, J. Butler.
Global epidemiology of heart failure.
Nat Rev Cardiol, 21 (2024), pp. 717-734
[4]
A. Sicras-Mainar, A. Sicras-Navarro, B. Palacios, L. Varela, J.F. Delgado.
Epidemiología y tratamiento de la insuficiencia cardiaca en España: estudio PATHWAYS-HF.
Rev Esp Cardiol (Engl Ed), 75 (2022), pp. 31-38
[5]
C. Escobar, B. Palacios, L. Varela, et al.
Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain.
J Clin Med, 11 (2022), pp. 5199
[6]
T.A. McDonagh, M. Metra, M. Adamo, et al.
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J, 42 (2021), pp. 3599-3726
[7]
A. Cannata, T.A. McDonagh.
Heart failure with preserved ejection fraction.
N Engl J Med, 392 (2025), pp. 173-184
[8]
B.A. Borlaug, K. Sharma, S.J. Shah, J.E. Ho.
Heart failure with preserved ejection fraction: JACC scientific statement.
J Am Coll Cardiol, 81 (2023), pp. 1810-1834
[9]
K.S. Shah, H. Xu, R.A. Matsouaka, et al.
Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes.
J Am Coll Cardiol, 70 (2017), pp. 2476-2486
[10]
C.E. Hamo, C. DeJong, N. Hartshorne-Evans, et al.
Heart failure with preserved ejection fraction.
Nat Rev Dis Primers, 10 (2024), pp. 55
[11]
M.E. Guisado-Espartero, P. Salamanca-Bautista, Ó. Aramburu-Bodas, et al.
Causes of death in hospitalized patients in internal medicine departments with heart failure according to ejection fraction. RICA registry.
Med Clin (Barc), 158 (2022), pp. 13-19
[12]
S.M. Dunlay, V.L. Roger, J.M. Killian, et al.
Advanced heart failure epidemiology and outcomes: a population-based study.
JACC Heart Fail, 9 (2021), pp. 722-732
[13]
S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, E. Bocchi, M. Böhm, et al.
EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction.
N Engl J Med, 385 (2021), pp. 1451-1461
[14]
S.D. Solomon, J.J.V. McMurray, B. Claggett, R.A. de Boer, D. DeMets, A.F. Hernandez, et al.
DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.
N Engl J Med, 387 (2022), pp. 1089-1098
[15]
T.A. McDonagh, M. Metra, M. Adamo, et al.
2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J, 44 (2023), pp. 3627-3639
[16]
M. Buonafine, B. Bonnard, F. Jaisser.
Mineralocorticoid receptor and cardiovascular disease.
Am J Hypertens, 31 (2018), pp. 1165-1174
[17]
P. Kolkhof, F. Jaisser, S.Y. Kim, G. Filippatos, C. Nowack, B. Pitt.
Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside.
Handb Exp Pharmacol, 243 (2017), pp. 271-305
[18]
G. Savarese, F. Lindberg, G. Filippatos, J. Butler, S.D. Anker.
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists.
Diabetologia, 67 (2024), pp. 246-262
[19]
A.K. Pandey, D.L. Bhatt, F. Cosentino, et al.
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Eur Heart J, 43 (2022), pp. 2931-2945
[20]
F. Le Billan, J. Perrot, E. Carceller, et al.
Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells.
FASEB J, 35 (2021),
[21]
L.C. Liu, E. Schutte, R.T. Gansevoort, P. van der Meer, A.A. Voors.
Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
Expert Opin Investig Drugs, 24 (2015), pp. 1123-1135
[22]
V. Marzolla, M. Infante, A. Armani, M. Rizzo, M. Caprio.
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Expert Opin Drug Saf, 21 (2022), pp. 1161-1170
[23]
E.V. Lerma, D.J. Wilson.
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
Expert Rev Clin Pharmacol, 15 (2022), pp. 501-513
[24]
U. Kintscher.
Cardiovascular and renal benefit of novel non-steroidal mineralocorticoid antagonists in patients with diabetes.
Curr Cardiol Rep, 25 (2023), pp. 1859-1864
[25]
J.L. Górriz, J.R. González-Juanatey, L. Facila, M.J. Soler, A. Valle, A. Ortiz.
Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease.
Nefrologia (Engl Ed), 43 (2023), pp. 386-398
[27]
A. Oiwa, D. Hiwatashi, T. Takeda, et al.
Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes.
J Clin Endocrinol Metab, 108 (2023), pp. 2203-2210
[28]
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Kidney Int, 105 (2024), pp. S117-S314
[29]
V. Perkovic, M.J. Jardine, B. Neal, et al.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
N Engl J Med, 380 (2019), pp. 2295-2306
[30]
H.J.L. Heerspink, B.V. Stefánsson, R. Correa-Rotter, et al.
Dapagliflozin in patients with chronic kidney disease.
N Engl J Med, 383 (2020), pp. 1436-1446
[31]
W.G. Herrington, N. Staplin, C. Wanner, et al.
Empagliflozin in patients with chronic kidney disease.
N Engl J Med, 388 (2023), pp. 117-127
[32]
G.L. Bakris, R. Agarwal, S.D. Anker, et al.
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.
N Engl J Med, 383 (2020), pp. 2219-2229
[33]
B. Pitt, G. Filippatos, R. Agarwal, et al.
Cardiovascular events with finerenone in kidney disease and type 2 diabetes.
N Engl J Med, 385 (2021), pp. 2252-2263
[34]
R. Agarwal, G. Filippatos, B. Pitt, et al.
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Eur Heart J, 43 (2022), pp. 474-484
[35]
American Diabetes Association Professional Practice Committee.
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025.
Diabetes Care, 48 (2025), pp. S239-S251
[36]
M.S. Khan, J.P. Lea.
Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.
BMC Nephrol, 25 (2024), pp. 248
[37]
F. Zannad, D.K. McGuire, A. Ortiz.
Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes.
J Intern Med, 297 (2025), pp. 460-478
[38]
S.D. Solomon, J.J.V. McMurray, M. Vaduganathan, et al.
Finerenone in heart failure with mildly reduced or preserved ejection fraction.
N Engl J Med, 391 (2024), pp. 1475-1485
[39]
M. Vaduganathan, B.L. Claggett, A.S. Desai, et al.
Estimated long-term benefits of finerenone in heart failure: a prespecified secondary analysis of the FINEARTS-HF randomized clinical trial.
JAMA Cardiol, 10 (2025), pp. 176-181
[40]
M. Chimura, M.C. Petrie, M. Schou, et al.
Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF.
Circ Heart Fail, 17 (2024),
[41]
J.H. Butt, P.S. Jhund, A.D. Henderson, et al.
Finerenone according to frailty in heart failure: a prespecified analysis of the FINEARTS-HF randomized clinical trial.
JAMA Cardiol, 10 (2025), pp. 829-840
[42]
M. Chimura, X. Wang, P.S. Jhund, et al.
Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial.
JAMA Cardiol, 10 (2025), pp. 59-70
[43]
J.W. Ostrominski, B.L. Claggett, A.S. Desai, et al.
Finerenone according to insulin resistance in heart failure: insights from the FINEARTS-HF trial.
Eur J Heart Fail, (2025),
[44]
J.H. Butt, P.S. Jhund, A.D. Henderson, et al.
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial.
Eur J Heart Fail, 27 (2025), pp. 1326-1341
[45]
J.H. Butt, P.S. Jhund, A.D. Henderson, et al.
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Lancet Diabetes Endocrinol, 13 (2025), pp. 107-118
[46]
M. Vaduganathan, B.L. Claggett, I.J. Kulac, et al.
Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure.
Circulation, 151 (2025), pp. 149-158
[47]
J.H. Butt, A.D. Henderson, P.S. Jhund, et al.
Finerenone, obesity, and heart failure with mildly reduced/preserved ejection fraction: prespecified analysis of FINEARTS-HF.
J Am Coll Cardiol, 85 (2025), pp. 140-155
[48]
J.P. Ferreira, M. Vaduganathan, B.L. Claggett, et al.
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: findings from FINEARTS-HF.
Eur J Heart Fail, (2025),
[49]
J.W. Ostrominski, F.R. Mc Causland, B.L. Claggett, et al.
Finerenone across the spectrum of kidney risk in heart failure: the FINEARTS-HF trial.
JACC Heart Fail, (2025),
[50]
S. Matsumoto, P.S. Jhund, A.D. Henderson, et al.
Initial decline in glomerular filtration rate with finerenone in HFmrEF/HFpEF: a prespecified analysis of FINEARTS-HF.
J Am Coll Cardiol, 85 (2025), pp. 173-185
[51]
O. Vardeny, M. Vaduganathan, B.L. Claggett, et al.
Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction.
JAMA Cardiol, 10 (2025), pp. 42-48
[52]
F.R. Mc Causland, M. Vaduganathan, B.L. Claggett, et al.
Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial.
J Am Coll Cardiol, 85 (2025), pp. 159-168
[53]
K.F. Docherty, A.D. Henderson, P.S. Jhund, et al.
Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial.
[54]
S.D. Solomon, J.J.V. McMurray, I.S. Anand, J. Ge, C.S.P. Lam, A.P. Maggioni, et al.
PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.
N Engl J Med, 381 (2019), pp. 1609-1620
[55]
J.W. Cunningham, B.L. Claggett, M. Vaduganathan, et al.
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial.
Eur J Heart Fail, 27 (2025), pp. 1487-1491
[56]
A.S. Bhatt, M. Vaduganathan, B.L. Claggett, et al.
Effects of finerenone on readmissions for heart failure: insights from the FINEARTS-HF trial.
[57]
T. Kondo, P.S. Jhund, A.D. Henderson, et al.
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of FINEARTS-HF.
Eur J Heart Fail, 27 (2025), pp. 1459-1471
[58]
J.W. Cunningham, S. Chatur, B.L. Claggett, et al.
Finerenone and outpatient worsening heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial.
JAMA Cardiol, 10 (2025), pp. 370-378
[59]
A.S. Desai, M. Vaduganathan, B.L. Claggett, et al.
Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial.
J Am Coll Cardiol, 85 (2025), pp. 106-116
[60]
M. Chimura, P.S. Jhund, A.D. Henderson, et al.
Efficacy and tolerability of finerenone according to the use and dosage of diuretics: a prespecified analysis of the FINEARTS-HF randomized clinical trial.
JAMA Cardiol, 10 (2025), pp. 979-989
[61]
S. Matsumoto, A.D. Henderson, P.S. Jhund, et al.
Finerenone and atrial fibrillation in heart failure: a secondary analysis of the FINEARTS-HF randomized clinical trial.
JAMA Cardiol, 10 (2025), pp. 696-707
[62]
M. Chimura, M. Yang, A.D. Henderson, et al.
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial.
Eur J Heart Fail, (2025),
[63]
J.H. Butt, P.S. Jhund, A.D. Henderson, et al.
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial.
Eur J Heart Fail, 27 (2025), pp. 1444-1458
[64]
J.W. Ostrominski, M. Vaduganathan, B.L. Claggett, et al.
Finerenone and New York Heart Association functional class in heart failure: the FINEARTS-HF trial.
JACC Heart Fail, (2025),
[65]
M. Yang, M. Chimura, C.S.P. Lam, et al.
Finerenone and Quality of life assessed using the EuroQol 5-Dimension Questionnaire Level-Sum-Score in patients with heart failure and mildly reduced or preserved ejection fraction.
[66]
M. Yang, A.D. Henderson, A. Talebi, et al.
Effect of finerenone on the KCCQ in patients with HFmrEF/HFpEF: a prespecified analysis of FINEARTS-HF.
J Am Coll Cardiol, 85 (2025), pp. 120-136
[67]
M. Vaduganathan, G. Filippatos, B.L. Claggett, et al.
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
Nat Med, 30 (2024), pp. 3758-3764
[68]
J.W. Ostrominski, J. Harrington, B.L. Claggett, et al.
Anthropometric measures, cardiovascular outcomes, and treatment effects of finerenone in cardiovascular-kidney-metabolic disease: pooled participant-level analysis of 3 global trials.
[69]
M.A. Pabon, G. Filippatos, B.L. Claggett, et al.
Finerenone Reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis.
J Am Coll Cardiol, 85 (2025), pp. 1649-1660
[70]
J.W. Ostrominski, G. Filippatos, B.L. Claggett, et al.
Efficacy and safety of finerenone in heart failure with preserved ejection fraction: a FINE-heart analysis.
JACC Heart Fail, 13 (2025),
[71]
J.W. Ostrominski, G. Filippatos, B.L. Claggett, et al.
Effect of finerenone on morbidity and mortality in CKD.
[72]
S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, et al.
CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial.
[73]
B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Claggett, et al.
TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction.
N Engl J Med, 370 (2014), pp. 1383-1392
[74]
M.N. Kosiborod, S.Z. Abildstrøm, B.A. Borlaug, J. Butler, S. Rasmussen, M. Davies, et al.
STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity.
N Engl J Med, 389 (2023), pp. 1069-1084
[75]
M.N. Kosiborod, M.C. Petrie, B.A. Borlaug, J. Butler, M.J. Davies, G.K. Hovingh, et al.
STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes.
N Engl J Med, 390 (2024), pp. 1394-1407
[76]
M. Packer, M.R. Zile, C.M. Kramer, S.J. Baum, S.E. Litwin, V. Menon, et al.
SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity.
N Engl J Med, 392 (2025), pp. 427-437
[77]
Bayer AG. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF). Available from: https://www.clinicaltrials.gov/study/NCT06024746, accessed Oct 2025.
[78]
Bayer AG. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF). Available from: https://clinicaltrials.gov/ct2/show/NCT06008197, accessed Oct 2025.
[79]
AstraZeneca. Study to Evaluate the Effect of Balcinrenone/​Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF). Available from: https://clinicaltrials.gov/ct2/show/NCT06307652, accessed Oct 2025.
[80]
Uppsala University. Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT). Available from: https://clinicaltrials.gov/ct2/show/NCT02901184, accessed Oct 2025.
[81]
Charite University, Berlin, Germany. Spironolactone in the Treatment of Heart Failure (SPIRIT-HF). Available from: https://clinicaltrials.gov/study/NCT04727073, accessed Oct 2025.
[82]
Boehringer Ingelheim. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure. Available from: https://clinicaltrials.gov/study/NCT06424288, accessed Oct 2025.
Idiomas
Revista Clínica Española (English Edition)
Article options
Tools
Supplemental materials